drug

PET

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
DEVICE
Pre-approval / investigational in the US
Developed by National Institute of Mental Health (NIMH)
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
DEVICE

Indications

Trials

2
Predicting Antipsychotic Discontinuation in Psychosis
NCT02884518—Unknown
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
NCT00942981—Completed

KOLs & investigators

2
Euitae Kim, Ph. D.
Karen F Berman, M.D.

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
National Institute of Mental Health (NIMH)
company
trial
Predicting Antipsychotic Discontinuation in Psychosis
NA
trial
Functional Relevance of Dopamine Receptors in Healthy Controls and Patients With Schizophrenia: Characterization Through [11C]NNC-112 and [18F]Fallypride Positron Emission Tomography
trial
indication
Schizophrenia
indication
Schizophrenia
indication
Psychotic Disorders
indication
Schizoaffective Disorder
indication
KOL
Euitae Kim, Ph. D.
KOL score —
person
Karen F Berman, M.D.
KOL score —
person